Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Pediatrics/Neonatology | Musculoskeletal
Rhabdomyosarcoma Clinical Trials
A listing of Rhabdomyosarcoma medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
Georgia
Savannah : Memorial University Medical Center
ARST0531: Randomized Study of Vincristine, Dactinomycin, and Cyclophosphamide (VAC) Versus VAC Alternating with Vincristine and Irinotecan (VI) for Patient with Intermediate-Risk Rhabdomyosarcoma (RMS)
Savannah : Memorial University Medical Center
ARST0921: A Randomized Phase II Trial of Bevacizumab (IND#7921, Avastin) and Temsirolimus (IND#61010, Torisel) in Combination with Intravenous Vinorelbine and Cyclophosphamide in Patients with Recurrent/Refractory Rhabdomyosarcoma
View More »
Atlanta : Children's Healthcare of Atlanta Childern Hosp - ATL
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Maryland
Baltimore : Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. John Hopkins
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Massachusetts
Boston : Dana Farber Cancer Institute DFCI (3)
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Oregon
Portland : OHSU Knight Cancer Institute
Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma
Washington
Seattle : Seattle Children's Hospital CPKC412A2114
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Australia
Parkville : Novartis Investigative Site
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Belgium
Bulgaria
Plovdiv : Teva Investigational Site 0103
PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma
Sofia : Teva Investigational Site 0101
PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma
Varna : Teva Investigational Site 0102
PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma
Canada
Toronto : Novartis Investigative Site
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Czech Republic
Praha 5 : Teva Investigational Site 0201
PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma
France
Bordeaux : Institut Bergonie
CREATE: Cross-tumoral Phase 2 With Crizotinib
Marseille : Assistance Publique - Hôpitaux de Marseille - Hôpital de La Timone
CREATE: Cross-tumoral Phase 2 With Crizotinib
Paris : Novartis Investigative Site
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Villejuif Cedex : Novartis Investigative Site
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Germany
Hungary
Budapest : Teva Investigational Site 0301
PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma
Italy
Bologna : Novartis Investigative Site
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Milano : Novartis Investigative Site
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Norway
United Kingdom
Newcastle Upon Tyne : Novartis Investigative Site
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Sutton : Novartis Investigative Site
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
